+Vote!
PharmaGossip (Free subscription) | 17 hours ago
In a move aimed at delivering new medicines to market more quickly and cheaply, Eli Lilly & Co. struck a $1.6 billion deal with drug-development service company Covance Inc., which will buy one of Lilly's research-and-development facilities for $50 million as part of the agreement. Lilly hopes Covance's expertise in conducting drug trials will shave months off the Indianapolis drug maker's early-stage...
+Vote!
Seeking Alpha (Free subscription) | 7 hours ago
Mike Huckman submits: In the latest move in the big pharma restructuring/outsourcing trend, on Wednesday morning, Eli Lilly (LLY) announced that it's selling a lab site in its home state of Indiana to the contract research organization Covance (CVD). A CRO does lab and clinical work for biopharma companies. LLY is also on the hook to give Covance about a billion-and-a-half dollars worth of business...
+Vote!
Indy Star (Free subscription) | 15 hours ago
In the drug industry, headliners such as Pfizer, Merck and Eli Lilly and Co. get most of the attention. But Covance, which offers a wide array of support functions, is the biggest behind-the-scenes player in a fast-growing field.
1Vote!
Law Blog - WSJ.com (Free subscription) | 19 hours ago
Eli Lilly struck a $1.6 billion deal with drug-development service company Covance, which will buy one of Lilly's research-and-development facilities for $50 million as part of the agreement.
+Vote!
The Star-Ledger (Free subscription) | yesterday
Covance today said it will buy Eli Lilly's 450-acre research campus in Greenfield, Indiana, for $50 million, and assume a key role in drug development for the struggling pharmaceutical company. The deal -- and a related services pact Lilly struck...
+Vote!
Virginia Biotechnology Association (Free subscription) | yesterday
Covance Inc., a leading provider of drug development services, announced August 6 that it signed a definitive agreement with Eli Lilly and Company to help transform Lilly’s R&D model. Under the agreement, Covance will acquire Lilly’s 450-acre...
+Vote!
Law Blog - WSJ.com (Free subscription) | yesterday
Eli Lilly and Covance agreed to a 10-year $1.6 billion drug-development deal. The alliance is intended to transform how Lilly approaches research and development.
+Vote!
The Business Journal of Phoenix (Free subscription) | 4 hours ago
InNexus Biotechnology Inc. is working with Covance Inc. testing a drug on monkeys for the prospective treatment of non-Hodgkin's lymphoma.
+Vote!
Seeking Alpha (Free subscription) | 6 hours ago
Hickey and Walters ( Bespoke ) submit: Below we highlight stocks in the S&P 1500 that are closest to their 52-week highs. As shown, Covance (CVD) is the closest, followed by WCN, ADPT, PRXL and HBHC. Key names on the list include AMGN, GIS, BAX, HNZ, JNJ, and QCOM. In green we highlight names that are close their all-time highs. Momentum investors find these stocks highly attractive, and the fact...
+Vote!
Indy Star (Free subscription) | 15 hours ago
Eli Lilly is selling Greenfield Laboratories to Covance for $50 million. Covance will offer jobs to all 260 Lilly employeesin toxicology and other drug-development positions.
+Vote!
Pharmalot (Free subscription) | yesterday
This is all about lowering R&D costs. So here’s the deal: Lilly will sell its Greenfield Laboratories site in Indiana and transfer operations to Covance, a big contract research organization, for an up-front payment of $50 million, and the two companies are also signing a 10-year service agreement worth about $1.6 billion. As a result, [...]
+Vote!
Fiercebiotech (Free subscription) | 08/05/2008
The rest of Wall Street ( except biotech ) may be suffering, but according to the Motley Fool , CRO stock is hot. Big Pharma and small biotech's outsourcing initiatives have been good news for CROs. Covance, Parexel, ICON, Charles River and WuXi PharmaTech have sustained impressive growth over the past year. These companies offer a range of services, from getting a new trial off the ground to dealing...
+Vote!
Inbox Robot: Swiss Reinsurance News (Free subscription) | 08/05/2008
Covance keeps up the momentum in Q2 US-based contract research organisation (CRO) Covance extended its robust first-quarter performance into the second quarter ended ...
